Regulatory product record
SEMINTRA 4 MG/ML ORAL SOLUTION
Product identity, ingredients and source provenance from the regulatory catalogue. Linked clinical evidence has a separate review status.
Owner information handout
Plain-language medication information to review with the owner. Open the handout to print it or download a PDF.
Product identity
- Brand name
- SEMINTRA 4 MG/ML ORAL SOLUTION
- DIN
- 02418126
- DPD drug code
- 90270
- Regulatory category
- APPROVED_VET_DRUG
- Market status
- MARKETED
- Route(s)
- ORAL
- Pharmaceutical form(s)
- SOLUTION
- Ingredients
- TELMISARTAN (4 MG)
- Species (DPD record)
- CATS
- Company
- BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. (DIN owner)
Source and provenance
- Source dataset
- health_canada_dpd_marketed
- Source snapshot date
- Not available in this source
- Source record key
- 90270
- Archive fingerprint (SHA-256)
- 85cc3ce208af3aa57018c3d14d83f90220c436baef7455384b6d48d9774e1c88
Linked clinical reference
Clinical entries are linked through the active molecule. Check their species, formulation, source and review status separately from this product record.
Clinical evidence
Pending clinical review (PROPOSED)Rule-based (RULE_BASED)— applies to the facts and dose entries in this species selection; individual source records retain their own status.
Indications2
Hypertension / RAAS blockade when direct AT1-receptor blockade desired; option when ACE inhibitors not tolerated (cough, hyperkalemia)
DogExtra-label (EXTRA_LABEL)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: Hypertension / RAAS blockade when direct AT1-receptor blockade desired; option when ACE inhibitors not tolerated (cough, hyperkalemia) — Extra-label (human drug)
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
No dose established in source edition (later literature supports feline use — beyond this file's sources)
CatNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Cat · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Indications table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: No dose established in source edition (later literature supports feline use — beyond this file's sources) — —
- Cat · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Indications table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Dose regimens2
This calculator performs arithmetic only on the sourced dosing field shown for each result — it does not verify the field's accuracy, does not select which field to use for a patient, and does not replace a veterinarian's order. Not for clinical use. Confirm every result against the primary source before dispensing.
Select a species above to calculate a dose.
Adverse effects202
No adverse reactions reported in animals (limited experience) — —
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Hypotension — Human signal
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Vomiting34 reports
- Diarrhoea33 reports
- Lethargy (see also Central nervous system depression in Neurological)25 reports
- Elevated blood urea nitrogen (BUN)21 reports
- Elevated creatinine20 reports
- Hyperkalaemia20 reports
- Proteinuria18 reports
- Decreased appetite17 reports
- Elevated serum alkaline phosphatase (ALP)16 reports
- Elevated symmetrical dimethylarginine (SDMA)15 reports
- Not eating15 reports
- Urinary tract infection15 reports
Cat
- Lack of efficacy - NOS106 reports
- Vomiting99 reports
- Weight loss45 reports
- Decreased appetite32 reports
- Elevated creatinine30 reports
- Death by euthanasia28 reports
- Dehydration27 reports
- Diarrhoea25 reports
- Lethargy (see also Central nervous system depression in 'Neurological')24 reports
- Inappetence19 reports
- Anaemia NOS18 reports
- Heart murmur17 reports
Monitoring1
Blood pressure; renal values and potassium when combined with other RAAS-active drugs
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Monitoring Parameters · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Contraindications1
Pregnancy
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Contraindications & Warnings table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Precautions4
Do not combine with ACE inhibitors — dual RAAS blockade increases kidney injury risk, hypotension, hyperkalemia
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Contraindications & Warnings table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
In experimental dogs, telmisartan 1 mg/kg beat enalapril for BP control — but no well-controlled clinical trials in dogs exist in this edition; ACE inhibitors remain first-line.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Losartan is a poor choice in dogs (relies on an active metabolite dogs don't produce); telmisartan needs no metabolic activation.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
ARBs are less likely than ACE inhibitors to cause hyperkalemia and are generally better tolerated in humans — the rationale when ACEi side effects force a switch.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Interactions3
ACE inhibitors — Dual blockade → renal injury/hypotension/hyperkalemia risk — avoid stacking
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Potassium supplements / K-sparing diuretics — Hyperkalemia risk (class effect)
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
NSAIDs — Reduced antihypertensive effect / renal risk (class precaution)
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Pharmacokinetics2
Half-life — Up to 15 h in dogs — longest/most lipophilic of ARBs
Other speciesNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Other species · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Metabolism — Direct active drug (no pro-drug conversion needed)
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Pregnancy / lactation considerations1
Do not use in pregnant animals (ARBs are fetotoxic — renin-angiotensin system role in fetal renal development).
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 760–762 (not in Plumb's 7th ed.) — Pregnancy & Lactation · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Literature references15
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomy.
Study summary not available in the imported record. Open the original citation to review the study.
- The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate.
Study summary not available in the imported record. Open the original citation to review the study.
- Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats.
Study summary not available in the imported record. Open the original citation to review the study.
- Renal and cardiac effects of the PDE9 inhibitor BAY 73-6691 in 5/6 nephrectomized rats.
Study summary not available in the imported record. Open the original citation to review the study.
- A validated bioanalytical method for the simultaneous estimation of telmisartan and gallic acid in rat plasma samples by high-performance thin-layer chromatography-mass spectrometry: Application to an oral pharmacokinetic study.
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration; Plumb DC. Plumb's Veterinary Drug Handbook. 7th ed. PharmaVet Inc; 2011.